Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Report and Forecast 2023-2031

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Report and Forecast 2023-2031

Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Outlook

The global CIDP treatment market size was valued at USD 3.68 billion in 2022 and is projected to grow at a CAGR of 6.90% during the forecast period of 2023-2031 to reach a value of USD 6.71 billion by 2031. The market growth can be attributed to the increasing prevalence of CIDP and the rising awareness about the condition.

Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market: Introduction

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disorder that affects the peripheral nerves. It leads to progressive weakness and sensory loss in the limbs due to the immune system attacking the myelin sheath, which protects the nerves. The treatment options for CIDP include immunosuppressive medications, intravenous immunoglobulin (IVIg), and corticosteroids. The increasing prevalence of CIDP, along with the growing awareness of the condition, is driving the demand for its treatment. Other factors such as advancements in diagnostics, increasing government initiatives, and the development of innovative treatment options are also expected to drive market growth.

Advancements in technology have played a significant role in the growth of the CIDP treatment market. Improved diagnostic techniques and the development of new therapies have made CIDP treatment more accessible and effective. This has expanded the reach of CIDP treatment and helped to meet the growing demand for services.

The CIDP treatment market is expected to continue to grow in the coming years as awareness of the condition increases, and new treatment options and technologies are developed to meet the needs of patients with CIDP. However, there are still significant barriers to accessing CIDP treatment, particularly in low- and middle-income countries, where access to healthcare services is often limited. Efforts are underway to address these barriers and improve access to CIDP treatment globally.

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology

CIDP is a rare disorder, with an estimated prevalence of 1 to 9 per 100,000 people worldwide. The condition affects people of all ages, but it is more common in adults and tends to be more prevalent in men than women. Early diagnosis and appropriate treatment are crucial for improving the quality of life and reducing the risk of long-term disability in patients with CIDP.

CIDP Treatment Market Segmentations

The market can be segmented based on therapeutic methods, diagnosis methods, route of administration, end-user, and region:

Market Breakup by Therapeutic Methods

  • Corticosteroids
  • Intravenous Immunoglobulin
  • Plasma Exchange
  • Immunotherapy
  • Stem Cell Transplant
  • Physical Therapy
  • Others
Market Breakup by diagnosis
  • Electrodiagnostic Testing
  • Nerve Conduction
  • Electromyography
  • Spinal Fluid Analysis
  • Others
Market Breakup by route of administration
  • Intravenous
  • Oral
  • Others
Market Breakup by End-User
  • Hospitals
  • Specialty Neurological Clinics
  • Research and Academic Laboratories
• Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
CIDP Treatment Market Scenario

The global CIDP treatment market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of CIDP, rising awareness about the condition, and the growing demand for innovative treatment options. One key driver of growth in the CIDP treatment market is the increasing prevalence of CIDP.

North America is currently the largest market for CIDP treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of CIDP, a well-established healthcare infrastructure, and strong investment in CIDP research and development. Europe is also a significant market for CIDP treatment, with countries such as the UK, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of CIDP, and government initiatives to address the condition. Asia Pacific is another region that is experiencing significant growth in the CIDP treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of CIDP, and the growing adoption of advanced diagnostic techniques. In addition, government initiatives to address CIDP are helping to drive the growth of the market in the region.

Key Players in the Global CIDP Treatment Market

The report provides a detailed analysis of the key players involved in the CIDP treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
  • Grifols, S.A.
  • Octapharma AG
  • Baxter International Inc.
  • Pfizer Inc.
  • CSL Behring LLC
  • MedDay SA
  • Shire plc
  • Takeda Pharmaceutical Company Limited
  • Teijin Limited
  • Momenta Pharmaceuticals, Inc.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Chronic Inflammatory Demyelinating Polyneuropathy Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
6.1 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Overview
6.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Historical Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Value (2016-2022)
6.2.1.2 Global Forecast Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Value (2023-2031)
6.3 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market by Therapeutic Method
6.3.1 Market Overview
6.3.1.1 Corticosteroids
6.3.1.2 Intravenous Immunoglobulin
6.3.1.3 Plasma Exchange
6.3.1.4 Immunotherapy
6.3.1.5 Stem Cell Transplant
6.3.1.6 Physical Therapy
6.3.1.7 Others
6.4 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market by Diagnosis
6.4.1 Market Overview
6.4.1.1 Electrodiagnostic Testing
6.4.1.2 Nerve Conduction
6.4.1.3 Electromyography
6.4.1.4 Spinal Fluid Analysis
6.4.1.5 Others
6.5 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market by Route of Administration
6.5.1 Market Overview
6.5.1.1 Intravenous
6.5.1.2 Oral
6.5.1.3 Others
6.6 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market by End User
6.6.1 Market Overview
6.6.1.1 Hospitals
6.6.1.2 Specialty Neurological Clinics
6.6.1.3 Research and Academic Laboratories
6.7 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market by Region
6.7.1 Market Overview
6.7.1.1 North America
6.7.1.2 Europe
6.7.1.3 Asia Pacific
6.7.1.4 Middle East and Africa
6.7.1.5 Latin America
7 North America Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
7.1 Market Share by Country
7.2 United States of America
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
7.3 Canada
7.3.1 Historical Trend (2016-2022)
7.3.2 Forecast Trend (2023-2031)
8 Europe Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
8.1 Market Share by Country
8.2 United Kingdom
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3 Germany
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4 France
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
8.5 Italy
8.5.1 Historical Trend (2016-2022)
8.5.2 Forecast Trend (2023-2031)
8.6 Others
9 Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
9.1 Market Share by Country
9.2 China
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Japan
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4 India
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5 ASEAN
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
9.6 Australia
9.6.1 Historical Trend (2016-2022)
9.6.2 Forecast Trend (2023-2031)
9.7 Others
10 Latin America Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
10.1 Market Share by Country
10.2 Brazil
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Argentina
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 Mexico
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Others
11 Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 United Arab Emirates
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 Nigeria
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 South Africa
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Others
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
12.4.1.1 US FDA
12.4.1.2 EU EMA
12.4.1.3 INDIA CDSCO
12.4.1.4 JAPAN PMDA
12.4.1.5 Others
13 Challenges and Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Analysis
13.3 Awareness and Prevention Gaps
14 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Grifols, S.A.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Octapharma AG
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Baxter International Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 CSL Behring LLC
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 MedDay SA
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Shire plc
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Takeda Pharmaceutical Company Limited
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Teijin Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Momenta Pharmaceuticals, Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
16 Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings